AC Immune SA
ACIU
$2.39
-$0.05-2.05%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.72M | 1.00K | 4.07M | 4.07M | 4.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.72M | 1.00K | 4.07M | 4.07M | 4.07M |
| Cost of Revenue | 60.80M | 59.99M | 60.83M | 61.88M | 63.27M |
| Gross Profit | -44.08M | -59.98M | -56.75M | -57.81M | -59.20M |
| SG&A Expenses | 17.03M | 16.57M | 16.04M | 16.48M | 16.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.65M | -1.67M | -1.48M | -1.34M | -1.40M |
| Total Operating Expenses | 76.18M | 74.89M | 75.38M | 77.02M | 78.42M |
| Operating Income | -59.46M | -74.89M | -71.31M | -72.95M | -74.35M |
| Income Before Tax | -60.14M | -74.26M | -71.11M | -72.76M | -74.24M |
| Income Tax Expenses | 11.00K | 12.00K | 12.70K | 12.50K | 13.60K |
| Earnings from Continuing Operations | -60.15 | -74.28 | -71.12 | -72.77 | -74.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.15M | -74.28M | -71.12M | -72.77M | -74.26M |
| EBIT | -59.46M | -74.89M | -71.31M | -72.95M | -74.35M |
| EBITDA | -57.60M | -73.02M | -69.45M | -71.09M | -72.47M |
| EPS Basic | -0.71 | -0.88 | -0.85 | -0.87 | -0.89 |
| Normalized Basic EPS | -0.44 | -0.55 | -0.53 | -0.54 | -0.55 |
| EPS Diluted | -0.71 | -0.88 | -0.85 | -0.87 | -0.89 |
| Normalized Diluted EPS | -0.44 | -0.55 | -0.53 | -0.54 | -0.55 |
| Average Basic Shares Outstanding | 339.70M | 336.56M | 335.43M | 335.28M | 335.14M |
| Average Diluted Shares Outstanding | 339.70M | 336.56M | 335.43M | 335.28M | 335.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
